Distribution deal Shangai, page-18

Yes, good point regarding the lack of leverage with regard to ZNO.

What if that leverage is provided from another pathway though?

Earlier this week I was reading about potential litigious actions taken by workers who had contracted COVID at their workplace. (In the USA). Yes, difficult to prove, as COVID could have been contracted on the way to work but still a significant concern for any corporation. A potential lawsuit in waiting. All it would take is for a worker to feel that their workplace has not provided appropriate protective COVID practices. Imagine, a product like ZNO is available but the workplace felt no obligation (leverage) to use it. This Duty of Care could become quite powerful, IMO.

So, as workplaces globally open back up, companies may indeed feel pressured to ensure that the workplace is safe from COVID. Thus, all OHS concerns/Risk Management protocols need to be rigorous and transparent.

As referred to by Dui above, "The London Underground mission, with regard to ZOONO, was to ensure that they could provide a safer customer and employee environment"

I am sure that most large global institutions will feel 'pressured' to adopt this mission as well. The leverage.

Thoughts?